Masitinib Triples ALS Survival Odds in Long-Term Phase 2b/3 Trial Analysis
A new analysis links masitinib to a 42% five-year ALS survival rate versus a 23.5% historical benchmark, with median survival nearly tripling.
Summary
A new preprint from AB Science reports that ALS patients treated with masitinib, a drug targeting immune cells in the brain, showed dramatically better survival than historical comparisons. In a group of 130 treated patients, 42.3% survived five years from disease onset — nearly double the expected rate of around 23.5%. Among the 55 longest-surviving patients, median overall survival reached 121 months, compared to a predicted 42 months. Nearly half of these long-term survivors maintained quality of life without mechanical breathing assistance. The drug works by blocking tyrosine kinase activity in microglia and mast cells, which are immune cells thought to drive ALS progression. A confirmatory randomized trial with 408 patients is now planned to validate these findings.
Detailed Summary
Amyotrophic lateral sclerosis, or ALS, is one of the most devastating neurodegenerative diseases, typically killing patients within two to five years of diagnosis. Any therapy that meaningfully extends survival would represent a major breakthrough, which is why new data on masitinib is drawing attention from the ALS and longevity research communities.
AB Science published a preprint on medRxiv analyzing long-term survivors from its phase 2b/3 AB10015 trial. Among 130 patients treated with masitinib at 4.5 mg/kg/day, the five-year survival rate from disease onset was 42.3%. In patients who had not yet lost full physical functionality, that figure climbed to 52.9%. Both numbers compare favorably against a historical benchmark of approximately 23.5%, suggesting masitinib may roughly double survival odds.
The most striking finding involves the 55 patients classified as long-term survivors. Their median overall survival reached 121 months — just over ten years — versus the 42 months predicted by the ENCALS prognostic model. That represents a residual median survival gain of 79 months, or more than six and a half additional years. Critically, 49% of these survivors maintained satisfactory quality of life without mechanical ventilation assistance.
Masitinib is a tyrosine kinase inhibitor. Unlike most ALS drugs that target neurons directly, masitinib focuses on microglia and mast cells — immune cells increasingly implicated in neuroinflammation and ALS progression. This mechanism aligns with growing research linking neuroinflammation to neurodegenerative disease broadly, making it relevant beyond ALS.
Important caveats apply. This is a company-sponsored preprint, not yet peer-reviewed, and survival comparisons rely on historical controls rather than a concurrent placebo arm, which introduces bias risk. The planned AB23005 trial, randomizing 408 patients to masitinib plus riluzole versus placebo plus riluzole, will provide the rigorous confirmatory evidence needed before clinical adoption.
Key Findings
- Masitinib-treated ALS patients showed a 42.3% five-year survival rate versus a 23.5% historical benchmark.
- Long-term survivors on masitinib had a median overall survival of 121 months versus 42 months predicted.
- Masitinib targets microglia and mast cells, addressing neuroinflammation rather than neurons directly.
- 49% of long-term survivors maintained quality of life without mechanical ventilation assistance.
- A 408-patient confirmatory randomized trial, AB23005, is planned to validate these results.
Methodology
This is a news report summarizing a company-sponsored medRxiv preprint, which has not yet undergone peer review. The evidence basis is a retrospective long-term survivor analysis from a phase 2b/3 trial using historical controls rather than a concurrent randomized placebo group, limiting causal inference.
Study Limitations
Results come from a company-sponsored preprint not yet peer-reviewed, and survival gains are compared to historical benchmarks rather than a concurrent control arm, which can inflate apparent benefit. The confirmatory AB23005 trial will be essential to verify these findings before drawing firm clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.